<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556398</url>
  </required_header>
  <id_info>
    <org_study_id>2015-07</org_study_id>
    <nct_id>NCT02556398</nct_id>
  </id_info>
  <brief_title>Use of Mobile-based Technologies to Improve Diabetes Self-management and Postprandial Glucose Control</brief_title>
  <official_title>Use of Mobile-based Technologies to Improve Diabetes Self-management and Postprandial Glucose Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project involve evaluation of a web-based nutrition education program and pilot-testing&#xD;
      of a new smartphone app for real-time data logging to identify factors causing glycemic&#xD;
      variability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intervention will be three (3) months in duration and will entail use of a smart phone&#xD;
      app for real-time data logging to identify factors causing glycemic variability, as well as&#xD;
      use of a web-based nutrition education program. The investigators postulate that the&#xD;
      interactive nutrition education curriculum - which will provide feedback to patients about&#xD;
      the inter-relationship between their food intake and postprandial glucose profiles, as well&#xD;
      as practical guidance for improvements - will lead to a change in food choices and improved&#xD;
      post-prandial glucose control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Actual">January 22, 2021</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under the curve (AUC) above target (&gt; 180 mg/dL)</measure>
    <time_frame>3 months</time_frame>
    <description>Amount of time spent above &gt;180 mg/dL on CGM Freestyle Libre readings</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Intervention - Educ Module and App</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm to be given smartphone app (&quot;Sugar Sleuth&quot;) and educational module.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Sugar Sleuth</intervention_name>
    <description>Educational module and use of smart phone app (&quot;Sugar Sleuth&quot;)</description>
    <arm_group_label>Intervention - Educ Module and App</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Individuals that satisfy all of the following conditions will be considered for&#xD;
        participation:&#xD;
&#xD;
          1. Must be between the ages of 25 - 75 years of age (inclusive)&#xD;
&#xD;
          2. Type 1 diabetes diagnosis at least 1 year, treated with multiple daily injections or&#xD;
             insulin pump.&#xD;
&#xD;
          3. A1c 7.5-9.0%&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Current or past use of real-time CGM for more than 2 months.&#xD;
&#xD;
          2. Pregnancy (self-reported) or planning conception in next 6 months.&#xD;
&#xD;
          3. History of disordered eating, actively trying to lose weight or planning to do so, BMI&#xD;
             &gt; 30 kg/m2 (to limit participation by individuals who are actively trying to lose&#xD;
             weight),&#xD;
&#xD;
          4. Medical conditions or medications that would affect gastric emptying such as&#xD;
             gastroparesis, bariatric surgery, medications such as pramlinitide, liraglutide or&#xD;
             exenatide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Toschi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02556398/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

